- Ongoing, recruitingTherapeutic confirmatory (Phase III)
J2T-MC-KGBI/DRM06-AD13: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy, Safety and Pharmacokinetics of Lebrikizumab Compared to Placebo in Participants 6 Months to <18 Years of Age with Moderate-to-Severe Atopic Dermatitis
This study is testing a new medicine called lebrikizumab for children and teenagers aged 6 months to under 18 years with moderate to severe eczema. We want to see if it helps improve their skin and is safe compared to a dummy medicine.
For: Atopic Dermatitis EczemaPoland · Spain · Czechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3b, Open-label Study to Evaluate the Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis
This study looks at a new treatment called Lebrikizumab for adults and teenagers with moderate to severe eczema. We want to see how well it works and if it's safe. The main goal is to find out how many people see a big improvement in their eczema after 24 weeks.
For: Atopic DermatitisGermany · Netherlands - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A 2-year Open-label Extension Study to Assess the Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis
This study is looking at the long-term safety and effectiveness of a new medicine called Lebrikizumab for adults and teenagers with moderate to severe eczema (atopic dermatitis). We want to see how well it works over two years and if there are any side effects.
For: Atopic DermatitisGermany · Poland - Active not recruitingPHASE3
Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
This study looks at how well a new medicine, lebrikizumab, works and if it's safe for teenagers and adults with moderate to severe eczema. It wants to see if the medicine can improve skin symptoms over 24 weeks.
For: Atopic Dermatitis · EczemaGermany · Netherlands · United Kingdom